ClinicalTrials.gov

History of Changes for Study: NCT01843504
Platelet-Rich Plasma (PRP) Injection for the Treatment of Chronic Patellar Tendinopathy (PRP)
Latest version (submitted October 6, 2022) on ClinicalTrials.gov
  • A study version is represented by a row in the table.
  • Select two study versions to compare. One each from columns A and B.
  • Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only applies to the Protocol section of the study.
  • Click "Compare" to do the comparison and show the differences.
  • Select a version's Submitted Date link to see a rendering of the study for that version.
  • The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
  • Hover over the "Recruitment Status" to see how the study's recruitment status changed.
  • Study edits or deletions are displayed in red.
  • Study additions are displayed in green.
Study Record Versions
Version A B Submitted Date Changes
1 April 25, 2013 None (earliest Version on record)
2 May 1, 2013 Study Description, Study Status, References and Outcome Measures
3 October 9, 2015 Study Status
4 May 4, 2017 Study Status
5 May 1, 2018 Study Status
6 September 6, 2018 Study Status and Study Identification
7 May 30, 2019 Oversight and Study Status
8 March 26, 2020 Recruitment Status and Study Status
9 April 3, 2020 Study Status
10 October 27, 2020 Recruitment Status and Study Status
11 March 24, 2021 Study Status
12 March 3, 2022 Study Status
13 October 6, 2022 Outcome Measures, Study Status, Study Description and Study Identification
Comparison Format:

Scroll up to access the controls

Study NCT01843504
Submitted Date:  April 25, 2013 (v1)

Open or close this module Study Identification
Unique Protocol ID: 2012-0723
Brief Title: Platelet-Rich Plasma (PRP) Injection for the Treatment of Chronic Patellar Tendinopathy (PRP)
Official Title: The Clinical, Biomechanical, and Tissue Regenerating Effects of a Single Platelet-rich Plasma Injection for the Treatment of Chronic Patellar Tendinopathy: a Randomized Controlled Trial
Secondary IDs:
Open or close this module Study Status
Record Verification: April 2013
Overall Status: Enrolling by invitation
Study Start: March 2013
Primary Completion: March 2014 [Anticipated]
Study Completion: March 2014 [Anticipated]
First Submitted: April 25, 2013
First Submitted that
Met QC Criteria:
April 25, 2013
First Posted: April 30, 2013 [Estimate]
Last Update Submitted that
Met QC Criteria:
April 25, 2013
Last Update Posted: April 30, 2013 [Estimate]
Open or close this module Sponsor/Collaborators
Sponsor: University of Wisconsin, Madison
Responsible Party: Sponsor
Collaborators:
Open or close this module Oversight
U.S. FDA-regulated Drug:
U.S. FDA-regulated Device:
Data Monitoring: No
Open or close this module Study Description
Brief Summary: The goal of this study is to find an effective treatment for chronic patellar tendinopathy (PT). We will conduct a 32-week randomized controlled clinical trial to determine whether platelet rich plasma (PRP) injections improve disease-specific clinical outcomes with correlation to a new method of ultrasound (US) imaging assessment called Acoustoelastography (AE). Positive findings of PRP compared to control would suggest future larger scale studies to help establish an optimal protocol for the nonsurgical management of PT.
Detailed Description:

This study is a randomized, single-blinded controlled trial. Adult subjects, aged 18-65 with chronic patellar tendinopathy (PT), will be recruited through the University of Wisconsin (UW) Sports Medicine Clinics and the UW Physical Therapy Clinics. 44 subjects will be randomized to one of two study arms (22 in each group). Subjects and assessors will be blinded to the subject group allocation.

Subjects in Group 1 (PRP) will receive a single US-guided injection of 5 mL autologous platelet-rich plasma at week 0 (baseline). Subjects in Group 2 (saline control) will receive a single injection of 5 mL 0.9% normal saline at week 0. Subjects in both groups will receive just one session of injection.

Subjects invited to participate in the study will be asked to undergo a knee evaluation examination. Tender areas associated with the patellar tendon will be identified. This exam will occur at the US Sports Medicine Clinic at Research Park. If patient is being seen by PI for a routine clinic visit for knee pain, they may be identified as a potential research participant. During the clinic visit, the patient will undergo a knee evaluation examination. If they are confirmed to have patellar tendinopathy, the PI will introduce the study. If interested, the PI will conduct a brief in-person interview to determine eligibility via selfreported inclusion and exclusion criteria. Subjects who qualify will have written consent obtained prior to their knee exam.

Subjects will then report to WIMR where the ultrasound-guided procedures and follow-up diagnostic imaging will be conducted. The study coordinator will greet the subjects, remind them of the details of the study procedure, its potential benefits and risks, and answer questions. Dr. Lee will then meet the subject, answer any questions and assess vital signs.

The RN will prepare a 3 mL syringe of 1% lidocaine with a 30G, ½" long needle for pre-injection topical analgesia (skin wheal).

The RN will then perform a blood draw of 15 mL of the subject's own blood from the antecubital fossa of the elbow using a 20 mL syringe and an 18G needle. There is no side preference. Control subjects will also undergo phlebotomy to maintain blinding. This is a small amount of blood; Red Cross donations of one unit of whole blood are typically 450 mL. The study coordinator will then place the sample in the Platelet Separator System (a centrifuge) and spin the blood sample in using a two-stage spinning: the 1st separates red blood cells from platelets, and the 2nd concentrates the platelets. This will be spun by centrifuge to yield 6 mL of concentrated autologous platelet. All blood and equipment handling will follow universal precautions.

Ultrasound will serve as visual guidance for injections. Dr. Lee will perform all ultrasound-guided injections. The injection technique is identical for subjects in the two injection groups. The skin will be cleansed with chloraprep. Lidocaine skin wheals will be placed for local analgesia. The origin of the patellar tendon of the affected knee will be identified using the ultrasound12MHz linear array transducer. Under continuous ultrasound evaluation, 1.0-2.0 mL of the prepared PRP or saline solution will be injected onto the origin of the patella tendon itself using a 22G, 1.5" long needle. Then, 3.0 to 4.0 mL of the PRP or saline solution will be peppered along a short segment of the tendon into the areas of palpated tenderness and US-documented pathology.

Ultrasound guided PRP injections and follow-up ultrasound will be performed at WIMR's Ultrasound Imaging Research Lab. The WIMR Ultrasound research program will provide the equipment (Siemens S2000), linear array probes, and supplies for injections. The WIMR Ultrasound research program will provide the research sonographer (Sarah Kohn). This is important in maintaining consistency in imaging protocol, image acquisition, and subject satisfaction, which also influences outcomes of research studies.

After the injections, the subjects will rest for 5 minutes and the study coordinator will then obtain the subject's vital signs. Subjects will be asked to complete outcome questionnaires. Participants will be given 20 tablets of 500mg acetaminophen for "as-needed" analgesia and will be telephoned after 2 days to enquire about side effects or adverse events outcome assessment procedures.

The platelet concentration will be analyzed in both samples (whole blood compared to PRP) in order to verify the concentration factor in PRP. Platelet counts in whole blood vary by individual. The optimal quantity of platelets and growth factors required for tissue healing is not known, but a clinically effective concentration has been described as being greater than 4 times baseline autologous whole blood platelet concentrations (Marx RE: Platelet-rich plasma: Evidence to support its use. J Oral Maxillofac Surg 2004;62:489-496.) Therefore, platelet concentration yield may have important implications in clinical outcome correlation. Following the procedure, approximately 1 mL of autologous whole blood and 1 mL of unused PRP will be analyzed using a standard lab automated analyzer, a Horiba ABX Micros 60 hematology cytometer, at the UW Health Research Park Clinic.

Subjects will complete outcome questionnaires at weeks 0, 4, 8, 12, 16, and 32 weeks. The questionnaires for weeks 4, 8, 12 and 16, along with self-addressed stamped envelopes will be provided to study participants at the time of enrollment in their study folder. Questionnaires will be returned at the time of the indicated due date at the top of the questionnaires. If subjects do not return their questionnaires, a member of the study team will contact the subjects by phone as a reminder, and the participant will be invited to complete the survey by phone. Ultrasound imaging will be performed at baseline and 32 weeks. On the final visit, participants will report for a scheduled visit to the WIMR clinic for their 32 week ultrasound visit. They will complete their 32 week questionnaires at that time if they have not already done so.

Open or close this module Conditions
Conditions: Chronic Patellar Tendinopathy
Chronic PT
Keywords: platelet rich plasma
PRP
plasma
plasma injection
patellar tendinopathy
patella tendon
patella
ultrasound
shear wave ultrasound
tendinosis
tendinopathy
tendinitis
jumper's knee
Open or close this module Study Design
Study Type: Interventional
Primary Purpose: Treatment
Study Phase: Phase 2
Interventional Study Model: Parallel Assignment
Number of Arms: 2
Masking: Single (Participant)
Allocation: Randomized
Enrollment: 44 [Anticipated]
Open or close this module Arms and Interventions
Arms Assigned Interventions
Active Comparator: Platelet Rich Plasma
Subjects in Group 1 (PRP) will receive a single US-guided injection of 5 mL autologous platelet-rich plasma at week 0 (baseline).
Biological: platelet rich plasma
A blood draw of 15 mL of the subject's own blood will be performed. The study coordinator will then place the sample in the Platelet Separator System (a centrifuge) and spin the blood sample in using a two-stage spinning: the 1st separates red blood cells from platelets, and the 2nd concentrates the platelets. This will be spun by centrifuge to yield 6 mL of concentrated autologous platelet. Under continuous ultrasound evaluation, 1.0-2.0 mL of the prepared PRP will be injected onto the origin of the patella tendon itself will be peppered along a short segment of the tendon into the areas of palpated tenderness and US-documented pathology.
Placebo Comparator: Group 2
Subjects in Group 2 (saline control) will receive a single injection of 5 mL 0.9% normal saline at week 0.
saline
A blood draw of 15 mL of the subject's own blood will be performed to maintain blinding. Under continuous ultrasound evaluation, 1.0-2.0 mL of the saline solution will be injected onto the origin of the patella tendon itself will be peppered along a short segment of the tendon into the areas of palpated tenderness and US-documented pathology.
Open or close this module Outcome Measures
Primary Outcome Measures:
1. Outcome questionnaire score evaluation
[ Time Frame: One year ]

Subjects will complete outcome questionnaires at weeks 0, 4, 8, 12, 16, and 32 weeks. The results will report evaluate improved pain- and function-dependent, knee-specific quality of life, as assessed by composite scores on the validated Victorian Institute of Sport Assessment-Patellar (VISAP), International Knee Documentation Committee (IKDC), and knee injection questionnaires. The results of the Groups 1 and 2 will be compared.
Secondary Outcome Measures:
1. Ultrasound evaluation of changes of pathologic features
[ Time Frame: One year ]

Ultrasound (US) changes of several pathologic features of PT will be evaluated using US imaging of the patellar tendon at 32 weeks compared to baseline imagin. Conventional ultrasound will be done to assess thickness (contralateral comparison), neovascularity, and hypoechogenicity; and Acoustoelastography (AE) will be done to measure stiffness changes of the patellar tendon using standardized 0-3 severity scales compared to control subjects.
Other Outcome Measures:
1. Evaluation of subject satisfaction of PRP therapy
[ Time Frame: One year ]

Outcome measures will be compared for satisfaction with PRP therapy as assessed by the treatment satisfaction survey score at 32 weeks post-treatment.
Open or close this module Eligibility
Minimum Age: 18 Years
Maximum Age: 65 Years
Sex: All
Gender Based:
Accepts Healthy Volunteers: Yes
Criteria:

Inclusion Criteria:

  1. age18-65
  2. chronic (>3months) patellar tendon pain;
  3. clinical exam findings consistent with PT;
  4. self-reported failure of supervised physical therapy;
  5. self-reported failure of at least 2 of the most common treatments (NSAIDs, relative rest, ice, bracing) for patellar tendinopathy.

Exclusion Criteria:

  1. inability to comply with follow-up requirements of study,
  2. history of bleeding disorders, low-platelet counts, other hematologic conditions;
  3. knee pain due to another possible etiology(e.g., degenerative joint disease);
  4. current or recent use of anticoagulation or immunosuppressive therapy;
  5. known allergy to acetaminophen or Lidocaine;
  6. self-reported pregnancy;
  7. worker's compensation injury;
  8. pending litigation;
  9. concurrent opioid use for pain
Open or close this module Contacts/Locations
Study Officials: John J. Wilson, MD, MS
Principal Investigator
UW-Madison School of Medicine & Public Health
Stephen J. Almasi, MD
Principal Investigator
UW-Madison School of Medicine & Public Health
Kenneth S. Lee, MD
Principal Investigator
UW-Madison School of Medicine & Public Health
Locations: United States, Wisconsin
Wisconsin Institute of Medical Research
Madison, Wisconsin, United States, 53705
UW Sports Medicine Clinic at Research Park
Madison, Wisconsin, United States, 53711
Open or close this module IPDSharing
Plan to Share IPD:
Open or close this module References
Citations:
Links:
Available IPD/Information:

Scroll up to access the controls Scroll to the Study top

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services